Cargando…

Almonertinib-induced interstitial lung disease: A case report

RATIONALE: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have elicited favorable anti-tumor activity in non-small cell lung cancer especially the lung adenocarcinoma. Interstitial lung disease (ILD) is 1 of the fatal side effects of EGFR-TKIs. However, such type of side eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Ting, Luo, Yiyang, Wang, Binbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837903/
https://www.ncbi.nlm.nih.gov/pubmed/33546082
http://dx.doi.org/10.1097/MD.0000000000024393
_version_ 1783643050452451328
author Jiang, Ting
Luo, Yiyang
Wang, Binbin
author_facet Jiang, Ting
Luo, Yiyang
Wang, Binbin
author_sort Jiang, Ting
collection PubMed
description RATIONALE: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have elicited favorable anti-tumor activity in non-small cell lung cancer especially the lung adenocarcinoma. Interstitial lung disease (ILD) is 1 of the fatal side effects of EGFR-TKIs. However, such type of side effect has not been observed in the follow-up during the treatment of the third-generation EGFR-TKI Almonertinib (also called HS-10296). Here, we first report an Almonertinib-induced ILD in an elderly female patient. PATIENT CONCERNS: A 70-year-old female diagnosed with “ lung adenocarcinoma with intracranial metastasis” harboring a mutation of EGFR 19DEL was administrated with Almonertinib 110 mg orally as the first-line treatment. However, she presented with chest tightness, and shortness of breath, accompanying with paroxysmal dry cough 3 months after the initiation of Almonertinib. DIAGNOSES: Extensive relevant examinations did not provide conclusive results and the chest computed tomography showed a diffuse ILD in bilateral pulmonary. INTERVENTIONS: The patient was diagnosed with Almonertinib-induced ILD in the absence of no other potential causes. She discontinued Almonertinib and was treated with oxygen uptaken and methylprednisolone. OUTCOMES: The whole symptoms were eliminated and the chest computed tomography showed ILD got remission after the prescription of methylprednisolone. LESSONS: Almonertinib has potential to cause the rare but severe interstitial lung disease. Clinicians should keep cautious of this when prescribing Almonertinib.
format Online
Article
Text
id pubmed-7837903
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-78379032021-01-27 Almonertinib-induced interstitial lung disease: A case report Jiang, Ting Luo, Yiyang Wang, Binbin Medicine (Baltimore) 5700 RATIONALE: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have elicited favorable anti-tumor activity in non-small cell lung cancer especially the lung adenocarcinoma. Interstitial lung disease (ILD) is 1 of the fatal side effects of EGFR-TKIs. However, such type of side effect has not been observed in the follow-up during the treatment of the third-generation EGFR-TKI Almonertinib (also called HS-10296). Here, we first report an Almonertinib-induced ILD in an elderly female patient. PATIENT CONCERNS: A 70-year-old female diagnosed with “ lung adenocarcinoma with intracranial metastasis” harboring a mutation of EGFR 19DEL was administrated with Almonertinib 110 mg orally as the first-line treatment. However, she presented with chest tightness, and shortness of breath, accompanying with paroxysmal dry cough 3 months after the initiation of Almonertinib. DIAGNOSES: Extensive relevant examinations did not provide conclusive results and the chest computed tomography showed a diffuse ILD in bilateral pulmonary. INTERVENTIONS: The patient was diagnosed with Almonertinib-induced ILD in the absence of no other potential causes. She discontinued Almonertinib and was treated with oxygen uptaken and methylprednisolone. OUTCOMES: The whole symptoms were eliminated and the chest computed tomography showed ILD got remission after the prescription of methylprednisolone. LESSONS: Almonertinib has potential to cause the rare but severe interstitial lung disease. Clinicians should keep cautious of this when prescribing Almonertinib. Lippincott Williams & Wilkins 2021-01-22 /pmc/articles/PMC7837903/ /pubmed/33546082 http://dx.doi.org/10.1097/MD.0000000000024393 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 5700
Jiang, Ting
Luo, Yiyang
Wang, Binbin
Almonertinib-induced interstitial lung disease: A case report
title Almonertinib-induced interstitial lung disease: A case report
title_full Almonertinib-induced interstitial lung disease: A case report
title_fullStr Almonertinib-induced interstitial lung disease: A case report
title_full_unstemmed Almonertinib-induced interstitial lung disease: A case report
title_short Almonertinib-induced interstitial lung disease: A case report
title_sort almonertinib-induced interstitial lung disease: a case report
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837903/
https://www.ncbi.nlm.nih.gov/pubmed/33546082
http://dx.doi.org/10.1097/MD.0000000000024393
work_keys_str_mv AT jiangting almonertinibinducedinterstitiallungdiseaseacasereport
AT luoyiyang almonertinibinducedinterstitiallungdiseaseacasereport
AT wangbinbin almonertinibinducedinterstitiallungdiseaseacasereport